Neoadjuvant therapy in pancreatic cancer

Roderick M. Quiros, Kimberly M. Brown, John P. Hoffman

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. Surgical resection offers the only hope of cure, though the addition of chemoradiation in the adjuvant setting has been shown to improve survival over surgery alone. Many patients are unable to receive adjuvant therapy due to prolonged postoperative recovery. For this reason, administration of chemoradiation preoperatively (neoadjuvant) has been proposed as an alternative to postoperative treatment. In patients with resectable disease, neoadjuvant therapy results in similar survivals compared to postoperative therapy, with a greater proportion of patients able to complete treatment. For selected patients with borderline or unresectable disease, neoadjuvant therapy offers the potential for tumor downstaging and increasing the likelihood of a margin-negative resection. This article reviews the use of neoadjuvant therapy in the treatment of pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)267-273
Number of pages7
JournalCancer Investigation
Volume25
Issue number4
DOIs
StatePublished - May 2007
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Pancreatic Neoplasms
Therapeutics
Survival
Cause of Death
Neoplasms

Keywords

  • Chemo therapy
  • Induction therapy
  • Neoadjuvant therapy
  • Pancreatic cancer
  • Radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Quiros, R. M., Brown, K. M., & Hoffman, J. P. (2007). Neoadjuvant therapy in pancreatic cancer. Cancer Investigation, 25(4), 267-273. https://doi.org/10.1080/07357900701206356

Neoadjuvant therapy in pancreatic cancer. / Quiros, Roderick M.; Brown, Kimberly M.; Hoffman, John P.

In: Cancer Investigation, Vol. 25, No. 4, 05.2007, p. 267-273.

Research output: Contribution to journalArticle

Quiros, RM, Brown, KM & Hoffman, JP 2007, 'Neoadjuvant therapy in pancreatic cancer', Cancer Investigation, vol. 25, no. 4, pp. 267-273. https://doi.org/10.1080/07357900701206356
Quiros, Roderick M. ; Brown, Kimberly M. ; Hoffman, John P. / Neoadjuvant therapy in pancreatic cancer. In: Cancer Investigation. 2007 ; Vol. 25, No. 4. pp. 267-273.
@article{044e8f52af63418d8c67460ca5cf469e,
title = "Neoadjuvant therapy in pancreatic cancer",
abstract = "Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. Surgical resection offers the only hope of cure, though the addition of chemoradiation in the adjuvant setting has been shown to improve survival over surgery alone. Many patients are unable to receive adjuvant therapy due to prolonged postoperative recovery. For this reason, administration of chemoradiation preoperatively (neoadjuvant) has been proposed as an alternative to postoperative treatment. In patients with resectable disease, neoadjuvant therapy results in similar survivals compared to postoperative therapy, with a greater proportion of patients able to complete treatment. For selected patients with borderline or unresectable disease, neoadjuvant therapy offers the potential for tumor downstaging and increasing the likelihood of a margin-negative resection. This article reviews the use of neoadjuvant therapy in the treatment of pancreatic cancer.",
keywords = "Chemo therapy, Induction therapy, Neoadjuvant therapy, Pancreatic cancer, Radiation therapy",
author = "Quiros, {Roderick M.} and Brown, {Kimberly M.} and Hoffman, {John P.}",
year = "2007",
month = "5",
doi = "10.1080/07357900701206356",
language = "English (US)",
volume = "25",
pages = "267--273",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Neoadjuvant therapy in pancreatic cancer

AU - Quiros, Roderick M.

AU - Brown, Kimberly M.

AU - Hoffman, John P.

PY - 2007/5

Y1 - 2007/5

N2 - Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. Surgical resection offers the only hope of cure, though the addition of chemoradiation in the adjuvant setting has been shown to improve survival over surgery alone. Many patients are unable to receive adjuvant therapy due to prolonged postoperative recovery. For this reason, administration of chemoradiation preoperatively (neoadjuvant) has been proposed as an alternative to postoperative treatment. In patients with resectable disease, neoadjuvant therapy results in similar survivals compared to postoperative therapy, with a greater proportion of patients able to complete treatment. For selected patients with borderline or unresectable disease, neoadjuvant therapy offers the potential for tumor downstaging and increasing the likelihood of a margin-negative resection. This article reviews the use of neoadjuvant therapy in the treatment of pancreatic cancer.

AB - Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. Surgical resection offers the only hope of cure, though the addition of chemoradiation in the adjuvant setting has been shown to improve survival over surgery alone. Many patients are unable to receive adjuvant therapy due to prolonged postoperative recovery. For this reason, administration of chemoradiation preoperatively (neoadjuvant) has been proposed as an alternative to postoperative treatment. In patients with resectable disease, neoadjuvant therapy results in similar survivals compared to postoperative therapy, with a greater proportion of patients able to complete treatment. For selected patients with borderline or unresectable disease, neoadjuvant therapy offers the potential for tumor downstaging and increasing the likelihood of a margin-negative resection. This article reviews the use of neoadjuvant therapy in the treatment of pancreatic cancer.

KW - Chemo therapy

KW - Induction therapy

KW - Neoadjuvant therapy

KW - Pancreatic cancer

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=34347377540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347377540&partnerID=8YFLogxK

U2 - 10.1080/07357900701206356

DO - 10.1080/07357900701206356

M3 - Article

VL - 25

SP - 267

EP - 273

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 4

ER -